Aug 102020
 August 10, 2020  Posted by  Business

Elise Reuter reports:

A deal involving one of the largest direct-to-consumer genetic testing companies has raised questions about what it will mean for users’ data. Private equity firm Blackstone will acquire for $4.7 billion.

Blackstone will take a 75% stake in the company, with one of Ancestry’s previous  investors, GIC, holding the remaining 25%, anonymous sources told Bloomberg.

Read more on MedCity News

Sorry, the comment form is closed at this time.